article · Viruses
This study investigated the rates of virological failure and mortality among people living with HIV in Rwanda who transitioned to second- or third-line antiretroviral therapy between 2019 and 2025. Using national surveillance data, researchers found that 10.4% experienced virological failure and 1.7% died. Key factors associated with poorer outcomes included receiving a PI-based regimen and having advanced WHO clinical stages III or IV. The findings suggest a need for enhanced viral load monitoring, adherence support, and individualised treatment reviews for patients on PI-based therapy, alongside systematic implementation of the WHO advanced HIV disease package for those with advanced disease.
This research is crucial for improving HIV treatment strategies in Rwanda. By identifying specific patient groups and treatment types at higher risk of virological failure or death, it enables healthcare providers to tailor monitoring and care, ultimately enhancing treatment effectiveness and patient survival rates for people living with HIV.
The abstract does not indicate a direct commercialisation pathway for a new product or service. Instead, the findings are intended to inform and improve clinical guidelines and public health strategies for managing HIV patients in Rwanda, particularly regarding monitoring, adherence support, and regimen review.
AI-generated from the published abstract. Always read the original work before citing.
BACKGROUND: Despite Rwanda's achievement of the UNAIDS 95-95-95 targets, national evidence on virological failure (VF) and mortality after transition to second- or third-line antiretroviral therapy (ART) remains limited. We estimated the incidence of these outcomes and examined associated factors among people living with HIV (PLWH) transitioned to second- or third-line ART in Rwanda between 2019 and 2025. METHODS: We conducted a retrospective cohort study using Rwanda's national HIV case-based surveillance (CBS) system. PLWH aged ≥15 years who transitioned to second- or third-line ART between 1 January 2019 and 31 December 2025 were followed from transition until the first recorded outcome, last clinical contact, or administrative censoring. The primary operational VF endpoint was the first viral load >1000 copies/mL recorded ≥180 days after transition; a prespecified sensitivity analysis required two consecutive measurements >1000 copies/mL. We used Kaplan-Meier estimation and facility-clustered Cox regression for the composite outcome of VF or death, and Aalen-Johansen cumulative incidence functions and Fine-Gray regression for VF with death treated as a competing event. RESULTS: Among 778 PLWH followed for 3564 person-years (median follow-up, 60.0 months), 81 (10.4%) met the primary operational VF endpoint, and 13 (1.7%) had death recorded as the first event. The composite incidence rate was 2.64 per 100 person-years (95% CI 2.10-3.17). In adjusted Cox regression, a PI-based regimen (adjusted hazard ratio [aHR] 2.14, 95% CI 1.37-3.36), WHO stage III (aHR 1.92, 95% CI 1.10-3.34), and WHO stage IV (aHR 3.59, 95% CI 1.61-8.02) were associated with the composite outcome. In Fine-Gray analysis, a PI-based regimen (subdistribution hazard ratio [sHR] 3.37, 95% CI 1.96-5.78) and WHO stage IV (sHR 4.44, 95% CI 1.91-10.4) were associated with VF. CONCLUSIONS: PI-based regimen use and advanced WHO clinical stage were associated with poorer outcomes after ART line transition. These findings support intensified viral load monitoring, adherence and resistance assessment, and individualized regimen review for patients receiving PI-based therapy, together with systematic implementation of the WHO advanced HIV disease package for patients with stage III or IV disease.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/v18080905
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
